# To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray

> **NCT04817800** · PHASE1,PHASE2 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 48 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)

## Key facts

- **NCT ID:** NCT04817800
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2021-04-10
- **Final completion:** 2021-04-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817800, "To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04817800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*